VioQuest to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
October 20, 2005 08:00 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 20, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to speak at the C.E. Unterberg, Towbin Emerging Growth Life Sciences...
VioQuest Completes Merger with Greenwich Therapeutics; Acquires Oncology Compounds
October 19, 2005 08:00 ET
|
VioQuest Pharmaceuticals
Raises $8.4 Million in Private Placement
Acquisition Establishes Strong Pipeline of Phase I/II Targeted
Oncology Therapeutics
MONMOUTH JUNCTION, N.J. Oct. 19,...
VioQuest to Present at BIO InvestorForum 2005
October 17, 2005 10:28 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 17, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH), will be presenting at the BIO InvestorForum 2005 Conference at 11:20 AM PST Thursday, October 20th...
VioQuest Pharmaceuticals Named One of 50 Fastest Growing Companies in New Jersey by 'New Jersey's Finest'
October 12, 2005 09:10 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 12, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH) was named among "New Jersey's 50 Finest" by NJBIZ Magazine. The Company was honored in an awards...
VioQuest Pharmaceuticals Reports 45 Percent Increase in Revenue for Fiscal Third Quarter 2005
October 05, 2005 08:00 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 5, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) reported revenue of approximately $533,000 for the third quarter of 2005 compared to $367,000 for the...
VioQuest Pharma Subsidiary Signs License Agreement with Merck to Supply Chiral Catalysts and Ligands
September 15, 2005 08:00 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Sept. 15, 2005 (PRIMEZONE) -- VioQuest's subsidiary Chiral Quest, Inc., (OTCBB:VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the...
VioQuest's Proposed Drug Acquisition Candidate Enters Phase I Clinical Trial at Cleveland Clinic Cancer Center
September 13, 2005 09:10 ET
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J, Sept. 13, 2005 (PRIMEZONE) -- The Cleveland Clinic Taussig Cancer Center has initiated patient enrollment for a Phase I clinical trial of sodium stibogluconate (SSG), an...